Clinical application progress of tofacitinib in rheumatoid arthritis
10.3760/cma.j.cn341190-20200622-01107
- VernacularTitle:托法替布在类风湿关节炎治疗中的临床应用进展
- Author:
Shuifang CHEN
1
;
Wenlin SHU
Author Information
1. 厦门市中医院药学部，厦门 361000
- Keywords:
Arthritis,rheumatoid;
Molecular targeted therapy;
Treatment outcome;
Review;
Tofacitinib
- From:
Chinese Journal of Primary Medicine and Pharmacy
2022;29(10):1594-1596
- CountryChina
- Language:Chinese
-
Abstract:
Tofacitinib is a novel targeted drug for the treatment of rheumatoid arthritis. With the entry into the medical insurance catalogue, the drug will usher in a new era. This paper reviews the effectiveness and safety of tofacitinib in the treatment of rheumatoid arthritis. Generally speaking, tofacitinib has definite efficacy, few adverse reactions, and controllable safety. Tofacitinib has an advantage over biological agents, that is, tofacitinib can be orally administered. Therefore, tofacitinib is especially developed for patients who have a poor response to or who are intolerant to disease-modifying antirheumatic drugs and biological agents. However, the effectiveness and safety of tofacitinib in a Chinese population need to be confirmed by more studies.
